HopeStage
Back to all studies
CompletedNCT03337646

Lisdexamfetamine in Children With ADHD and Autism

About this titleRead the official source — NCT03337646
Medication studyAges 6–12Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: 6 years to 12 years.

Listed locations
OttawaSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 26, 2018
Recruitment status
Completed
Enrollment listed in the registry
48
Sponsor
JPM van Stralen Medicine Professional
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Canada
Age range
From 6 Years to 12 Years
Official registry ID
NCT03337646
Official title
Show the full official title

A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Ottawa

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is JPM van Stralen Medicine Professional, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Lisdexamfetamine Dimesylate.

Who was this study for?

Listed age limits: 6 years to 12 years.

Want to explore more studies?

Explore studies